Impact of Oncotype DX® on Treatment Recommendation and Its Economic Evaluation Under the Brazilian Society Perspective

CompletedOBSERVATIONAL
Enrollment

155

Participants

Timeline

Start Date

August 8, 2018

Primary Completion Date

February 4, 2019

Study Completion Date

February 4, 2019

Conditions
Breast CancerAdjuvant Treatment
Interventions
GENETIC

Oncotype DX® Assay

After surgery, tumoral tissue was used to perform Oncotype Dx®. Patients were evaluated and therapy recommendations - adjuvant chemotherapy (CT) plus hormone therapy (HT) or HT alone - were captured before and after revealing the test results. Results from TAILORx10 were used to guide decisions for or against CT for individual patients. Changes in treatment recommendations were obtained.

OTHER

Cost

Changes in treatment costs were estimated from Pérola Byington Hospital.

Trial Locations (1)

04112080

Andre Mattar, São Paulo

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Fleury Laboratory

UNKNOWN

lead

Hospital Perola Byington

OTHER_GOV

NCT05100277 - Impact of Oncotype DX® on Treatment Recommendation and Its Economic Evaluation Under the Brazilian Society Perspective | Biotech Hunter | Biotech Hunter